Tags : CELLINK

PharmaShots Weekly Snapshot (February 03-07, 2020)

Tuba Khan February 10, 2020

WHO to Accelerate Global Research and Innovation Against Corona Virus Published: Feb 06, 2020 | Tags: WHO, Accelerate, Global, Research, Innovation, Against, Corona Virus 2. Curis Amends its Existing Collaboration […]readmore

Pharma

CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery

Vartika Singh February 4, 2020

Shots: CELLINK expand the collaboration for 12 months and will provide bioprinters and bioinks for acceleration of the exploration of novel targets in AstraZeneca’s 5 main therapy areas: oncology, respiratory, […]readmore

Tags : CELLINK

PharmaShots Weekly Snapshot (February 03-07, 2020)

CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : CELLINK

PharmaShots Weekly Snapshot (February 03-07, 2020)

CELLINK Expands its Multi-Target Collaboration with AstraZeneca for Drug Discovery

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company